drugset
drugset / Trial / NCT07707973

Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma

NCT07707973 ↗

Phase 2 Not yet recruiting 50 enrolled Tianjin First Central Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm study. The study population consists of adult patients with a confirmed diagnosis of EGFR-positive high-grade glioma who have radiographic residual tumor following surgical resection. Participants will receive nimotuzumab in combination with the standard Stupp regimen after glioma surgery.

Timeline

Start
2026-07-03
Primary completion
2028-01-03
Completion
2029-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 200 mg Intravenous
Background Temozolomide Small molecule 150 mg/m2 Oral
Background Temozolomide Small molecule 200 mg/m2 Oral

Indications

malignant glioma